Pathophysiology and treatment of the dyslipidemia of insulin resistance.
Cohn, G
Pathophysiology and treatment of the dyslipidemia of insulin resistance. [electronic resource] - Current cardiology reports Sep 2001 - 416-23 p. digital
Publication Type: Journal Article; Review
1523-3782
10.1007/s11886-001-0059-0 doi
Cardiovascular Diseases--epidemiology
Enzyme Inhibitors--therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use
Hyperlipidemias--physiopathology
Hypoglycemic Agents--therapeutic use
Hypolipidemic Agents--therapeutic use
Insulin Resistance
Lactones--therapeutic use
Life Style
Lipase--antagonists & inhibitors
Metformin--therapeutic use
Niacin--therapeutic use
Orlistat
Risk Factors
Pathophysiology and treatment of the dyslipidemia of insulin resistance. [electronic resource] - Current cardiology reports Sep 2001 - 416-23 p. digital
Publication Type: Journal Article; Review
1523-3782
10.1007/s11886-001-0059-0 doi
Cardiovascular Diseases--epidemiology
Enzyme Inhibitors--therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use
Hyperlipidemias--physiopathology
Hypoglycemic Agents--therapeutic use
Hypolipidemic Agents--therapeutic use
Insulin Resistance
Lactones--therapeutic use
Life Style
Lipase--antagonists & inhibitors
Metformin--therapeutic use
Niacin--therapeutic use
Orlistat
Risk Factors